ATE485375T1 - Nukleinsäuren zum auslösen der tumorzellsterblichkeit - Google Patents
Nukleinsäuren zum auslösen der tumorzellsterblichkeitInfo
- Publication number
- ATE485375T1 ATE485375T1 AT04817274T AT04817274T ATE485375T1 AT E485375 T1 ATE485375 T1 AT E485375T1 AT 04817274 T AT04817274 T AT 04817274T AT 04817274 T AT04817274 T AT 04817274T AT E485375 T1 ATE485375 T1 AT E485375T1
- Authority
- AT
- Austria
- Prior art keywords
- nucleic acids
- tumor cell
- cell mortality
- trigger tumor
- trigger
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/13—Decoys
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03292666A EP1526177A1 (de) | 2003-10-24 | 2003-10-24 | Nukleinsäuren zur Beeinflussung der Tumorzell Sterblichkeit |
| PCT/EP2004/012857 WO2005040378A1 (en) | 2003-10-24 | 2004-10-25 | Nucleic acids useful for triggering tumor cell lethality |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE485375T1 true ATE485375T1 (de) | 2010-11-15 |
Family
ID=34384721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04817274T ATE485375T1 (de) | 2003-10-24 | 2004-10-25 | Nukleinsäuren zum auslösen der tumorzellsterblichkeit |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7595302B2 (de) |
| EP (2) | EP1526177A1 (de) |
| JP (2) | JP4743789B2 (de) |
| CN (1) | CN1871350B (de) |
| AT (1) | ATE485375T1 (de) |
| AU (1) | AU2004284228B2 (de) |
| CA (1) | CA2542942C (de) |
| CY (1) | CY1111060T1 (de) |
| DE (1) | DE602004029699D1 (de) |
| DK (1) | DK1675954T3 (de) |
| ES (1) | ES2354359T3 (de) |
| PL (1) | PL1675954T3 (de) |
| PT (1) | PT1675954E (de) |
| SI (1) | SI1675954T1 (de) |
| WO (1) | WO2005040378A1 (de) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7476729B2 (en) * | 2003-10-24 | 2009-01-13 | Institut Curie | Dbait and uses thereof |
| EP1944369A1 (de) * | 2007-01-12 | 2008-07-16 | The Centre National de la Recherche Scientifique | Dbait und eigenständige Anwendungen davon |
| EP2304031A2 (de) | 2008-06-11 | 2011-04-06 | Bionucleon S.r.l. | Hemmung von hrp-3 unter verwendung modifizierter oligonukleotide |
| AU2015202211B2 (en) * | 2010-06-22 | 2016-09-01 | Centre National De La Recherche Scientifique | Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates |
| PL3135301T3 (pl) * | 2010-06-22 | 2018-11-30 | Onxeo | Zoptymalizowany system dostarczania in vivo z czynnikami andosomolitycznymi koniugatów kwasów nukleinowych |
| EP2527440A1 (de) * | 2011-05-27 | 2012-11-28 | Institut Curie | Krebsbehandlung durch Kombination von Doppelstrangbruch nachahmenden DNA-Molekülen mit Hyperthermie |
| JP6535333B2 (ja) * | 2013-09-04 | 2019-06-26 | シーエスアイアール | 遺伝子発現をサイレンシングする遺伝子制御エレメントを標的とする部位特異的ヌクレアーゼ単一細胞アッセイ |
| ES2888976T3 (es) * | 2014-06-23 | 2022-01-10 | Massachusetts Gen Hospital | Identificación no sesgada pangenómica de DSBs evaluada por secuenciación (GUIDE-Seq.) |
| EP3594343B1 (de) * | 2015-07-23 | 2021-04-21 | Institut Curie | Verwendung einer kombination aus dbait-molekül und parp-inhibitoren zur behandlung von krebs |
| KR102441432B1 (ko) * | 2016-03-01 | 2022-09-07 | 옹쎄오 | Ｄｂａｉｔ 분자의 전신 투여에 의한 암 치료법 |
| WO2017186882A1 (en) | 2016-04-29 | 2017-11-02 | Onxeo | A method of predicting a response to an anti-tumor treatment by means of signal interfering dna molecules |
| EP3484482A4 (de) | 2016-07-15 | 2020-07-29 | The Board of Regents of the University of Oklahoma | Anti-arid3a-behandlungen für entzündliche erkrankungen |
| WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
| EP3461488A1 (de) | 2017-09-27 | 2019-04-03 | Onxeo | Kombination aus einem dbait-molekül und einem hdac-inhibitor zur behandlung von krebs |
| CN108261548B (zh) * | 2018-01-10 | 2020-04-10 | 浙江大学 | 一种纳米复合物及其制备方法和应用 |
| JP2021515580A (ja) | 2018-03-13 | 2021-06-24 | オンクセオＯｎｘｅｏ | がんの治療における獲得耐性に対抗するｄｂａｉｔ分子 |
| CN112313241A (zh) | 2018-04-17 | 2021-02-02 | 总医院公司 | 核酸结合、修饰、和切割试剂的底物偏好和位点的灵敏体外试验 |
| EP3898974A1 (de) | 2018-12-21 | 2021-10-27 | Onxeo | Neue konjugierte nukleinsäuremoleküle und deren verwendungen |
| US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| TW202210633A (zh) | 2020-06-05 | 2022-03-16 | 法商昂席歐公司 | 用於治療癌症之dbait分子與kras抑制劑的組合 |
| TW202214857A (zh) | 2020-06-19 | 2022-04-16 | 法商昂席歐公司 | 新型結合核酸分子及其用途 |
| WO2023111203A1 (en) | 2021-12-16 | 2023-06-22 | Onxeo | New conjugated nucleic acid molecules and their uses |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0649467B1 (de) * | 1992-07-02 | 1998-09-16 | HYBRIDON, Inc. | Selbststabilisierte oligonukleotide als therapeutika |
| US6441158B1 (en) * | 1997-12-31 | 2002-08-27 | Medical College Of Georgia Research Institute, Inc. | Oligomers that bind to ku protein |
| EP0978561A1 (de) * | 1998-08-07 | 2000-02-09 | Hoechst Marion Roussel Deutschland GmbH | Antisense Oligonukleotide zur Hemmung von VEGF-Expression |
| US7060690B2 (en) * | 2001-01-22 | 2006-06-13 | Genta Incorporated | Methods and compositions for treating a cell-proliferative disorder using CRE decoy oligomers, BCL-2 antisense oligomers, and hybrid oligomers thereof |
| CA2476468A1 (en) | 2002-02-13 | 2003-08-21 | Medbridge, Inc. | Protein carrier system for therapeutic oligonucleotides |
| AU2003207708A1 (en) | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
-
2003
- 2003-10-24 EP EP03292666A patent/EP1526177A1/de not_active Withdrawn
-
2004
- 2004-10-25 DE DE602004029699T patent/DE602004029699D1/de active Active
- 2004-10-25 WO PCT/EP2004/012857 patent/WO2005040378A1/en active Application Filing
- 2004-10-25 CN CN200480031278.XA patent/CN1871350B/zh active Active
- 2004-10-25 EP EP04817274A patent/EP1675954B1/de active Active
- 2004-10-25 PL PL04817274T patent/PL1675954T3/pl unknown
- 2004-10-25 DK DK04817274.6T patent/DK1675954T3/da active
- 2004-10-25 US US10/576,818 patent/US7595302B2/en active Active
- 2004-10-25 SI SI200431547T patent/SI1675954T1/sl unknown
- 2004-10-25 ES ES04817274T patent/ES2354359T3/es active Active
- 2004-10-25 PT PT04817274T patent/PT1675954E/pt unknown
- 2004-10-25 CA CA2542942A patent/CA2542942C/en active Active
- 2004-10-25 JP JP2006536073A patent/JP4743789B2/ja active Active
- 2004-10-25 AT AT04817274T patent/ATE485375T1/de active
- 2004-10-25 AU AU2004284228A patent/AU2004284228B2/en active Active
-
2010
- 2010-12-23 CY CY20101101190T patent/CY1111060T1/el unknown
-
2011
- 2011-02-10 JP JP2011027662A patent/JP5662822B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011126897A (ja) | 2011-06-30 |
| EP1675954B1 (de) | 2010-10-20 |
| CY1111060T1 (el) | 2015-06-11 |
| JP2007510405A (ja) | 2007-04-26 |
| CA2542942C (en) | 2014-04-29 |
| JP4743789B2 (ja) | 2011-08-10 |
| PL1675954T3 (pl) | 2011-04-29 |
| WO2005040378A1 (en) | 2005-05-06 |
| US7595302B2 (en) | 2009-09-29 |
| US20070197458A1 (en) | 2007-08-23 |
| AU2004284228B2 (en) | 2010-04-08 |
| SI1675954T1 (sl) | 2011-01-31 |
| AU2004284228A1 (en) | 2005-05-06 |
| CN1871350B (zh) | 2014-10-15 |
| PT1675954E (pt) | 2010-12-27 |
| JP5662822B2 (ja) | 2015-02-04 |
| CN1871350A (zh) | 2006-11-29 |
| DK1675954T3 (da) | 2011-01-10 |
| DE602004029699D1 (de) | 2010-12-02 |
| ES2354359T3 (es) | 2011-03-14 |
| CA2542942A1 (en) | 2005-05-06 |
| EP1526177A1 (de) | 2005-04-27 |
| EP1675954A1 (de) | 2006-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1111060T1 (el) | Νουκλεϊκα οξεα χρησιμα για την πυροδοτηση της θνησιμοτητας κυτταρων ογκου | |
| CY1124931T1 (el) | Αντιμετωπιση της φαινυλκετονουριας με bh4 | |
| EP2481814A3 (de) | Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Krebs | |
| DE60327786D1 (de) | Kdr-peptide und diese enthaltende impfstoffe | |
| EP2730587A3 (de) | Gene zur Verbesserung der Stickstoffnutzungseffizienz bei Nutzpflanzen | |
| WO2004037977A3 (en) | Use of chimeric nucleases to stimulate gene targeting | |
| BRPI0510475B8 (pt) | adenovírus quimérico recombinante, uso do mesmo no tratamento de câncer e métodos de inibição de crescimento de uma célula de câncer, de fornecimento de uma proteína terapêutica a uma célula e para o isolamento do adenovírus | |
| AR051350A1 (es) | Vacuna de glucoproteina mucinosa (muc-1) | |
| WO2004044181A3 (en) | Antisense modulation of apolipoprotein b expression | |
| AR054526A1 (es) | Metodo para tartar pacientes con una vacuna de glicoproteina mucinosa (muc-1) | |
| DE60310202D1 (de) | Zielgerichtete chromosomale mutagenese mit zinkfingernukleasen | |
| DK1620140T3 (da) | Injicerbare tværbundne polymere præparater samt deres anvendelse | |
| CY1106056T1 (el) | Παραγωγα 2-αμινο-2-αλκυλ-5-επτενοϊκου και επτυνοϊκου οξεος χρησιμα σαν αναστολεις συνθασης νιτρικου οξειδιου | |
| DK1546174T3 (da) | Fremgangsmåder og sammensætninger til RNA-interferens | |
| EP2679246A3 (de) | Neue therapeutische Mittel und Methoden um Blindheit zu behandeln | |
| TR200202196T2 (tr) | Homolog yeniden kombine etmeyi iyileştirme yöntemleri | |
| WO2003097662A8 (en) | Antisense modulation of apolipoprotein b expression | |
| AR039185A1 (es) | Celulas hospedantes que tienen propiedades mejoradas de supervivencia celular y metodos para generar estas celulas | |
| WO2003105755A3 (en) | ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR C (VEGF-C) EXPRESSION | |
| GB0418388D0 (en) | Cell therapy | |
| EP1648910A4 (de) | Antisense-modulation der expression von stearoyl coa desaturase | |
| WO2003106640A3 (en) | CELL TARGETING METHODS AND COMPOSITIONS | |
| WO2004021978A3 (en) | Antisense modulation of endothelial specific molecule 1 expression | |
| DK1664102T3 (da) | Isoleret photoprotein mtclytin, samt dets anvendelse | |
| WO2005007098A3 (en) | Nucleic acid therapy to enhance cartilage repair |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1675954 Country of ref document: EP |